Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/Armata Pharmaceuticals, Inc./ 8-K

Current Report · Items 8.01, 9.01 · 8-K

Armata Pharmaceuticals, Inc.

ARMPNYSE_AMERICANEQUITYCurrent

Other Events

Item 8.01 Other Events. On September 23, 2026, Armata Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that it has received $3.7 million in additional non-dilutive funding from the U.S. Department of War (“DoW”) to support activities associated with the Phase 3 development program for AP-SA02, the Company’s intravenously administered Staphylococcus aureus (“S.…

Filed Sep 23, 2026Accepted Sep 23, 2026, 7:10 AM EDTCIK 921114Accession 0001104659-26-109809
View company →Permanent SEC source ↗
Share

Company context

Armata is a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other important pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage-specific current Good Manufacturing Practices (“cGMP”) manufacturing to support full commercialization.

Current securities

ARMPNYSE_AMERICAN · EQUITY · Current

Recent company filings

  1. Regulation FD DisclosureSep 14, 2026
  2. 10-Q filingAug 12, 2026
  3. Results of Operations and Financial ConditionAug 12, 2026
  4. Regulation FD DisclosureJul 20, 2026
  5. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsJul 20, 2026

Registered securities in this filing

ARMATA PHARMACEUTICALS, INC. · 8-K · Filed 2026-09-23

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock

Symbol
ARMP
Exchange
NYSEAMER
Classification
COMMON
Status
Current
Filing context

Context: AsOf2026-09-23

Dimensions: Not supplied

Accession 000110465926109809 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 8.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events. On September 23, 2026, Armata Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that it has received $3.7 million in additional non-dilutive funding from the U.S. Department of War (“DoW”) to support activities associated with the Phase 3 development program for AP-SA02, the Company’s intravenously administered Staphylococcus aureus (“S. aureus”) multi-phage product candidate for the adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus or methicillin-resistant S. aureus. The full text of the press release issued in connection with this announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
Filed exhibits (1)
EX-99.1 (by filename) tm2625977d1_ex99-1.htm

Exhibit 99.1 Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development Initial Phase 3-focused funding to support advancement of AP-SA02 in complicated Staphylococcus aureus bacteremia New commitment is incremental to previously announced DoW funding and expands total non-dilutive support for the AP-SA02 program to $32.4 million LOS ANGELES, Calif., September 23, 2026 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has received an additional $3.7 million in non-dilutive funds from the U.S. Department of War (“DoW”) to support activities associated with the Phase 3 development program for AP-SA02. Importantly, the $3.7 million represents the first funding received specifically for Phase 3 execution pursuant to a previously announced DoW award, received through the Medical Technology Enterpris…

Open exhibit ↗